(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCV)

(19) World Intellectual Property Organization

International Bureau



I DODIO SHINDON IN COMMO HADI SADIQ OSHIN BODA SI NI OSHIN SHIN SHIN BADA SHIN BOD DODION GARA DASH

(43) International Publication Date 24 June 2004 (24.06.2004)

(10) International Publication Number WO 2004/052930 A2

C07K 14/705, (51) International Patent Classification⁷: 14/54, 7/08, A61K 39/385, 9/127, 47/48

(21) International Application Number:

PCT/DK2003/000859

(22) International Filing Date:

11 December 2003 (11.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: DK 11 December 2002 (11.12.2002) PA 2002 01893 11 December 2002 (11.12.2002) US 60/432,532 12 February 2003 (12.02.2003) DK PA 2003 00198 US 12 February 2003 (12.02.2003) 60/446,707

(71) Applicant (for all designated States except US): PHARMEXA A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MOURITSEN, Søren [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).

- (74) Agent: INSPICOS A/S; Bøge Allé 3, P.O. Box 45, DK-2970 Hørsholm (DK).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TARGETING SINGLE EPITOPES

(57) Abstract: The invention relates to novel immunogenic agents that are capable of inducing specific B-cell immunity directed against one single epitope present in a self-antigen. The immunogenic agent is a chimeric binding protein that binds specifically to a first receptor, said first receptor being one that binds a second receptor present in an antigen of an animal, wherein said chimeric binding protein comprises: (a) a B-cell epitope in the form of a binding site that specifically binds the first receptor and which competes with the second receptor for binding to the first receptor, (b) a scaffold protein structure being autologous in said mammal, and (c) at least one tolerance breaking amino acid sequence, which is heterologous in said animal and which binds to an MHC Class II molecule in said animal. In preferred embodiments, the chimeric binding protein is in the form of an anti-idiotypic antibody having a tolerance-breaking aminoacid sequence introduced. The invention further relates to methods of preparing the immunogens and methods of using the immunogens in therapy. Also, the invention relates to proteins, nucleic acid fragments, recombinantly modified host cells and virus that are useful in the practice of the methods of the invention.



(19) World Intellectual Property **Organization**

International Bureau



1 (1511 | 1815) | 1 (1816 | 1816 | 1816 | 1816 | 1816 | 1816 | 1816 | 1816 | 1816 | 1816 | 1816 | 1816 | 1816 |

(43) International Publication Date 24 June 2004 (24.06.2004)

(10) International Publication Number WO 2004/052930 A3

(51) International Patent Classification7: C07K 14/705. 14/54, 7/08, A61K 39/385, 9/127, 47/48

(21) International Application Number:

PCT/DK2003/000859

(22) International Filing Date:

11 December 2003 (11.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11 December 2002 (11.12.2002) PA 2002 01893 DK 11 December 2002 (11.12.2002) US 60/432.532 12 February 2003 (12.02.2003) DK PA 2003 00198 US 60/446,707 12 February 2003 (12.02.2003)

(71) Applicant (for all designated States except US): PHARMEXA A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): MOURITSEN, Søren [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).
- (74) Agent: INSPICOS A/S; Bøge Allé 3, P.O. Box 45, DK-2970 Hørsholm (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 29 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TARGETING SINGLE EPITOPES



(57) Abstract: The invention relates to novel immunogenic agents that are capable of inducing specific B-cell immunity directed against one single epitope present in a self-antigen. The immunogenic agent is a chimeric binding protein that binds specifically to a first receptor, said first receptor being one that binds a second receptor present in an antigen of an animal, wherein said chimeric binding protein comprises: (a) a B-cell epitope in the form of a binding site that specifically binds the first receptor and which competes with the second receptor for binding to the first receptor, (b) a scaffold protein structure being autologous in said

mammal, and (c) at least one tolerance breaking amino acid sequence, which is heterologous in said animal and which binds to an MHC Class II molecule in said animal. In preferred embodiments, the chimeric binding protein is in the form of an anti-idiotypic antibody having a tolerance-breaking aminoacid sequence introduced. The invention further relates to methods of preparing the immunogens and methods of using the immunogens in therapy. Also, the invention relates to proteins, nucleic acid fragments, recombinantly modified host cells and virus that are useful in the practice of the methods of the invention.



Internal Carla Application No PCT/DK 03/00859

A CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/705 C07K14/54 A61K47/48

C07K7/08

A61K39/385

A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, CHEM ABS Data

C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	US 2003/228324 A1 (LUND GARRY ET AL) 11 December 2003 (2003-12-11) claim 8	1-56
P,X	WO 03 042244 A (BRATT TOMAS ;KLYSNER STEEN (DK); PHARMEXA AS (DK); VOLDBORG BJOERN) 22 May 2003 (2003-05-22) claims 1-48	1-56
X	WO 97 26784 A (ALEXANDER JEFFERY L; DEFREES SHAWN (US); CYTEL CORP (US); SETTE AL) 31 July 1997 (1997-07-31) claims 1-35	1-56
X	WO 99 58658 A (EPIMMUNE INC) 18 November 1999 (1999-11-18) claim 40	27-31
	-/	
X Furt	ther documents are listed in the continuation of box C. X Patent family	members are listed in annex.
° Special ca	ategories of cited documents : "T" later document pu	blished after the international filing date
"A" docum	ent defining the general state of the art which is not cited to understa dered to be of particular relevance invention	nd not in conflict with the application but and the principle or theory underlying the

Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.
"Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
19 April 2004	1 7. 05. 2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Filiswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer FERNANDO FARIETA /ELY
L	



International Application No PCT/DK 03/00859

Citation of document, with Indication, where appropriate, of the relevant passages WO 01 41741 A (CELIS ESTEBAN ;SIDNEY JOHN (US); CHESNUT ROBERT (US); EPIMMUNE INC) 14 June 2001 (2001-06-14) claims 1-39; example 7 LA ROSA CORINNA ET AL: "Preclinical development of an adjuvant-free peptide	Relevant to claim No.
(US); CHESNUT ROBERT (US); EPIMMUNE INC) 14 June 2001 (2001-06-14) claims 1-39; example 7 LA ROSA CORINNA ET AL: "Preclinical development of an adjuvant-free peptide	
development of an adjuvant-free peptide	21
vaccine with activity against CMV pp65 in HLA transgenic mice." BLOOD. UNITED STATES 15 NOV 2002, vol. 100, no. 10, 15 November 2002 (2002-11-15), pages 3681-3689, XP002277230 ISSN: 0006-4971 table 1	21
VOGEL M ET AL: "Mimicry of human IgE epitopes by anti-idiotypic antibodies." JOURNAL OF MOLECULAR BIOLOGY. ENGLAND 19 MAY 2000, vol. 298, no. 5, 19 May 2000 (2000-05-19), pages 729-735, XP002277231 ISSN: 0022-2836 figures 1-5	1-56
WEATHINGTON NATHANIEL M ET AL: "Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network." EXPERT REVIEW OF VACCINES. ENGLAND FEB 2003, vol. 2, no. 1, February 2003 (2003-02), pages 61-73, XP002277232 ISSN: 1476-0584 figure 3	1-56
US 2003/185845 A1 (BRATT TOMAS ET AL) 2 October 2003 (2003-10-02) claims 1-48	1-56
WO 95 17212 A (CORRADIN GIAMPIETRO ;HEALY FRANK (CH); MACH JEAN PIERRE (CH); BOEH) 29 June 1995 (1995-06-29) claims 1-11	1-56
WO 95 05849 A (ELSNER HENRIK ;MOURITSEN & ELSNER A S (DK); MOURITSEN SOEREN (DK)) 2 March 1995 (1995-03-02) claims 1-9	1-56
WO 95 07707 A (CYTEL CORP) 23 March 1995 (1995-03-23) claims 1-17	1-56
	vol. 100, no. 10, 15 November 2002 (2002-11-15), pages 3681-3689, XP002277230 ISSN: 0006-4971 table 1 VOGEL M ET AL: "Mimicry of human IgE epitopes by anti-idiotypic antibodies." JOURNAL OF MOLECULAR BIOLOGY. ENGLAND 19 MAY 2000, vol. 298, no. 5, 19 May 2000 (2000-05-19), pages 729-735, XP002277231 ISSN: 0022-2836 figures 1-5 WEATHINGTON NATHANIEL M ET AL: "Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network." EXPERT REVIEW OF VACCINES. ENGLAND FEB 2003, vol. 2, no. 1, February 2003 (2003-02), pages 61-73, XP002277232 ISSN: 1476-0584 figure 3 US 2003/185845 A1 (BRATT TOMAS ET AL) 2 October 2003 (2003-10-02) claims 1-48 WO 95 17212 A (CORRADIN GIAMPIETRO ;HEALY FRANK (CH); MACH JEAN PIERRE (CH); BOEH) 29 June 1995 (1995-06-29) claims 1-11 WO 95 05849 A (ELSNER HENRIK ;MOURITSEN & ELSNER A S (DK); MOURITSEN SOEREN (DK)) 2 March 1995 (1995-03-02) claims 1-9 WO 95 07707 A (CYTEL CORP) 23 March 1995 (1995-03-23)

International application No. PCT/DK 03/00859

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X Claims Nos.: 48-49, 55-56 because they relate to subject matter not required to be searched by this Authority, namely:	
see FURTHER INFORMATION sheet PCT/ISA/210	İ
2. X Claims Nos.: Part of 1-25,27-33,35-36,38-47,50-54 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210	
3. X Claims Nos.: 26, 34, 37 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
·	
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. .	
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

International Application No. PCT/ DK 03/00859

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 48-49, 55-56

Claims 48-49 and 55-56 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

Continuation of Box I.2

Claims Nos.: Part of 1-25,27-33,35-36,38-47,50-54

Part of present claims 1-25, 27-33, 35-36, 38-47, 50-54 relate to proteins, vectors, cells, compositions and methods defined by reference to desirable characteristics or properties of a "chimeric binding protein", which comprises three parts, namely:

a- Epitope (B-cell), that binds specifically and/or competitively, b- Scaffold protein structure, that stabilizes the 3D conformation, c- At least one "tolerance breaking amino acid sequence", that binds to an MHC class II molecule.

The claims cover all possible proteins, vectors, cells, compositions and methods having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of such proteins, vectors, cells, compositions and methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the proteins, vectors, cells, compositions and methods by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the proteins, vectors, cells, compositions and methods, those prepared in example 1 (only example) and part of claim 21 (part of sequences C.tetani/Padre).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a

International Application No. PCT/ DK 03/00859

eliminary examina	tion on matter w	hich has not h	peen searched. The	his is
eliminary examina e case irrespecti ceipt of the sear	ve of whether or ch report or dur	not the claim	ns are amended for II procedure.	ollowing
			•	

Internacional Application No PCT/DK 03/00859

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2003228324	A1	11-12-2003	US US	2003211114 6541007	A1 B1	13-11-2003 01-04-2003
WO 03042244	A	22-05-2003	WO US	03042244 2003185845		22-05-2003 02-10-2003
WO 9726784	A	31-07-1997	AT AU BR CA CN DE DK EP PT WO US	69714011 876398 0876398	A A A A D T T T A T T T T A A A A A A A	15-08-2002 20-08-1997 17-08-1999 31-07-1997 14-04-1999 22-08-2002 27-02-2003 12-08-2002 11-11-1998 16-12-2002 11-04-2000 31-12-2002 31-07-1997 02-07-2002
WO 9958658	Α	18-11-1999	AU CA EP JP WO US US US US	4078599 2331846 1078092 2002520000 9958658 6534482 2003216342 2003220285 2003203869 2003216343	A1 A2 T A2 B1 A1 A1 A1	29-11-1999 18-11-1999 28-02-2001 09-07-2002 18-11-1999 18-03-2003 20-11-2003 27-11-2003 30-10-2003 20-11-2003
WO 0141741	Α	14-06-2001	US AU CA EP JP WO US	6602510 2273701 2393730 1242049 2003516344 0141741 2003224036	A A1 A1 T A1	05-08-2003 18-06-2001 14-06-2001 25-09-2002 13-05-2003 14-06-2001 04-12-2003
US 2003185845	A1	02-10-2003	WO	03042244	A2	22-05-2003
WO 9517212	Α	29-06-1995	EP AU WO	0659438 1317695 9517212	Α	28-06-1995 10-07-1995 29-06-1995
WO 9505849	A	02-03-1995	AT AU AU CA DE DE WO EP GR	162723 707083 7009198 7608094 2170236 69408342 69408342 9505849 752886 0752886	B2 A A1 D1 T2 A1 T3 A1	15-02-1998 01-07-1999 30-07-1998 21-03-1995 02-03-1998 05-03-1998 14-05-1998 02-03-1995 04-05-1998 15-01-1997 01-04-1998 30-06-1998



International Application No PCT/DK 03/00859

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9505849	A		JP US	9505031 T 2002090379 A1	20-05-1997 11-07-2002
WO 9507707	A	23-03-1995	AU CN EP JP WO US	698962 B2 7873694 A 1135181 A 0735893 A1 9505559 T 9507707 A1 5736142 A 6413935 B1	12-11-1998 03-04-1995 06-11-1996 09-10-1996 03-06-1997 23-03-1995 07-04-1998 02-07-2002